Resource Effective Strategies to Prevent and Treat Cardiovascular Disease.

Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries. The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in low- and middle-income countries. Barriers at the patient, healthcare provider, and health system level prevent the implementation of optimal primary and secondary prevention. Identification of the particular barriers that exist in resource-constrained settings is necessary to inform effective strategies to reduce the identified evidence-practice gaps. Furthermore, targeting modifiable factors that contribute most significantly to the global burden of CVD, including tobacco use, hypertension, and secondary prevention for CVD, will lead to the biggest gains in mortality reduction. We review a select number of novel, resource-efficient strategies to reduce premature mortality from CVD, including (1) effective measures for tobacco control, (2) implementation of simplified screening and management algorithms for those with or at risk of CVD, (3) increasing the availability and affordability of simplified and cost-effective treatment regimens including combination CVD preventive drug therapy, and (4) simplified delivery of healthcare through task-sharing (nonphysician health workers) and optimizing self-management (treatment supporters). Developing and deploying systems of care that address barriers related to the above will lead to substantial reductions in CVD and related mortality.

[1]  S. Yusuf,et al.  Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data , 2016, The Lancet.

[2]  S. Yusuf,et al.  The environmental profile of a community’s health: a cross-sectional study on tobacco marketing in 16 countries , 2015, Bulletin of the World Health Organization.

[3]  S. Yusuf,et al.  Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach , 2015, BMC Health Services Research.

[4]  S. Yusuf,et al.  Adapting the World Heart Federation Roadmaps at the National Level: Next Steps and Conclusions. , 2015, Global Heart.

[5]  S. Yusuf,et al.  Reducing Premature Cardiovascular Mortality By 2025: The World Heart Federation Roadmap. , 2015, Global Heart.

[6]  S. Yusuf,et al.  Reducing Cardiovascular Disease Globally: The World Heart Federation's Roadmaps. , 2015, Global heart.

[7]  H. Mamudu,et al.  A Chilling Example? Uruguay, Philip Morris International, and WHO's Framework Convention on Tobacco Control. , 2015, Medical anthropology quarterly.

[8]  Mark D. Huffman,et al.  Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. , 2015, Global heart.

[9]  A. Reeves,et al.  Financing universal health coverage—effects of alternative tax structures on public health systems: cross-national modelling in 89 low-income and middle-income countries , 2015, The Lancet.

[10]  Andrew E Moran,et al.  Demographic and epidemiologic drivers of global cardiovascular mortality. , 2015, The New England journal of medicine.

[11]  Abigail S. Baldridge,et al.  Disparities in Cardiovascular Research Output and Citations From 52 African Countries: A Time‐Trend, Bibliometric Analysis (1999–2008) , 2015, Journal of the American Heart Association.

[12]  K. Charlton,et al.  A cross-sectional analysis of the cost and affordability of achieving recommended intakes of non-starchy fruits and vegetables in the capital of Vanuatu , 2015, BMC Public Health.

[13]  S. Bialous,et al.  Exposing and addressing tobacco industry conduct in low-income and middle-income countries , 2015, The Lancet.

[14]  Lisa Rosenbaum Beyond belief--how people feel about taking medications for heart disease. , 2015, The New England journal of medicine.

[15]  Bruce Neal,et al.  Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care: The Treatment of Cardiovascular Risk Using Electronic Decision Support Cluster-Randomized Trial , 2015, Circulation. Cardiovascular quality and outcomes.

[16]  S. Chatterjee,et al.  Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study. , 2014, Global heart.

[17]  Martin McKee,et al.  Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.

[18]  Stephen Jan,et al.  Task Shifting for Non-Communicable Disease Management in Low and Middle Income Countries – A Systematic Review , 2014, PloS one.

[19]  R. Marten,et al.  An assessment of progress towards universal health coverage in Brazil, Russia, India, China, and South Africa (BRICS) , 2014, The Lancet.

[20]  C. Murray,et al.  The Global Burden of Ischemic Heart Disease in 1990 and 2010: The Global Burden of Disease 2010 Study , 2014, Circulation.

[21]  N. Sarrafzadegan,et al.  Utilization of evidence-based therapy for acute coronary syndrome in high-income and low/middle-income countries. , 2014, The American journal of cardiology.

[22]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[23]  S. Yusuf,et al.  Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies , 2014, PloS one.

[24]  Alexandra Wollum,et al.  Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. , 2014, JAMA.

[25]  M. Weinstein,et al.  Who Needs Laboratories and Who Needs Statins?: Comparative and Cost-Effectiveness Analyses of Non–Laboratory-Based, Laboratory-Based, and Staged Primary Cardiovascular Disease Screening Guidelines , 2014, Circulation. Cardiovascular quality and outcomes.

[26]  J. Bosch,et al.  Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. , 2013, European Heart Journal.

[27]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[28]  D. Prabhakaran,et al.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.

[29]  Mark D. Huffman,et al.  Trends in Vascular Risk Factor Treatment and Control in US Stroke Survivors: The National Health and Nutrition Examination Surveys (1999–2010) , 2013, Circulation. Cardiovascular quality and outcomes.

[30]  Wei Li,et al.  Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. , 2013, JAMA.

[31]  Dolores Corella,et al.  Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[32]  D. Wald,et al.  Randomized Polypill Crossover Trial in People Aged 50 and Over , 2012, PloS one.

[33]  S. Yusuf,et al.  Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators , 2012, Circulation. Cardiovascular quality and outcomes.

[34]  M. Mckee,et al.  Manufacturing Epidemics: The Role of Global Producers in Increased Consumption of Unhealthy Commodities Including Processed Foods, Alcohol, and Tobacco , 2012, PLoS medicine.

[35]  J. Grimshaw,et al.  Knowledge translation of research findings , 2012, Implementation Science.

[36]  M. Mckee,et al.  Where There Is No Health Research: What Can Be Done to Fill the Global Gaps in Health Research? , 2012, PLoS medicine.

[37]  Stephen S. Lim,et al.  Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study , 2012, BMJ : British Medical Journal.

[38]  S. Kumanyika,et al.  Behavioral Strategies for Cardiovascular Risk Reduction in Diverse and Underserved Racial/Ethnic Groups , 2012, Circulation.

[39]  T. Brennan,et al.  Full coverage for preventive medications after myocardial infarction. , 2011, The New England journal of medicine.

[40]  M. Hill,et al.  Community Outreach and Cardiovascular Health (COACH) Trial: A Randomized, Controlled Trial of Nurse Practitioner/Community Health Worker Cardiovascular Disease Risk Reduction in Urban Community Health Centers , 2011, Circulation. Cardiovascular quality and outcomes.

[41]  S. Yusuf,et al.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.

[42]  R. Murray,et al.  What Factors Influence Smoking Prevalence and Smoke Free Policy Enactment across the European Union Member States , 2011, PloS one.

[43]  P. Lindsay,et al.  Canadian Hypertension Education Program: the science supporting New 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation. , 2011, The Canadian journal of cardiology.

[44]  Mark D. Huffman,et al.  A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries , 2011, PloS one.

[45]  T. Novotny,et al.  UN resolution on the prevention and control of non-communicable diseases: An opportunity for global action , 2011, Global public health.

[46]  N. Steyn,et al.  The cost of a healthy diet: a South African perspective. , 2011, Nutrition.

[47]  Martin McKee,et al.  Priority actions for the non-communicable disease crisis , 2011, The Lancet.

[48]  R. Collins,et al.  Diabetes mellitus, fasting glucose, and risk of cause-specific death. , 2011, The New England journal of medicine.

[49]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Journal of the American College of Cardiology.

[50]  Michele Cecchini,et al.  Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness , 2010, The Lancet.

[51]  Hayden B Bosworth,et al.  Patient self-management support: novel strategies in hypertension and heart disease. , 2010, Cardiology clinics.

[52]  A. Yan,et al.  Optimal Medical Therapy for Non–ST-Segment–Elevation Acute Coronary Syndromes: Exploring Why Physicians Do Not Prescribe Evidence-Based Treatment and Why Patients Discontinue Medications After Discharge , 2010, Circulation. Cardiovascular quality and outcomes.

[53]  C. Clark,et al.  Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[54]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[55]  P. Volberding,et al.  Antiretroviral therapy and management of HIV infection , 2010, The Lancet.

[56]  N. Ford,et al.  A systematic review of task- shifting for HIV treatment and care in Africa , 2010, Human resources for health.

[57]  Tezeta F. Mitiku,et al.  Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors , 2009, Canadian Medical Association Journal.

[58]  T. Ahmed,et al.  Community-based skilled birth attendants in Bangladesh: attending deliveries at home , 2009, Reproductive health matters.

[59]  S. Leeder,et al.  Coronary heart disease epidemics: not all the same , 2008, Heart.

[60]  P. Austin,et al.  Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction , 2008, Canadian Medical Association Journal.

[61]  C. Mathers,et al.  Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use , 2007, The Lancet.

[62]  F. Farzadfar,et al.  Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs , 2007, The Lancet.

[63]  Simon Capewell,et al.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.

[64]  S. Nishtar,et al.  Can non-physician health-care workers assess and manage cardiovascular risk in primary care? , 2007, Bulletin of the World Health Organization.

[65]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[66]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[67]  Guilbert Jj The World Health Report 2006: working together for health. , 2006 .

[68]  Murray Stewart,et al.  Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[69]  Milton C Weinstein,et al.  Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis , 2006, The Lancet.

[70]  G. Guyatt,et al.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.

[71]  J. Wylie-Rosett,et al.  Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.

[72]  S. Yusuf,et al.  WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). , 2005, Bulletin of the World Health Organization.

[73]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[74]  M. Jacobs,et al.  Human resources for health: overcoming the crisis , 2004, The Lancet.

[75]  John X. Morris,et al.  The Fat of the Land: Do Agricultural Subsidies Foster Poor Health? , 2004, Environmental Health Perspectives.

[76]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[77]  A. Fendrick,et al.  Suboptimal statin adherence and discontinuation in primary and secondary prevention populations , 2004, Journal of General Internal Medicine.

[78]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[79]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[80]  A. Dyer,et al.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.

[81]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[82]  Christopher J L Murray,et al.  WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty , 2003, BMJ : British Medical Journal.

[83]  D. Yach WHO Framework Convention on Tobacco Control , 2003, The Lancet.

[84]  O. Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[85]  R Brian Haynes,et al.  Helping patients follow prescribed treatment: clinical applications. , 2002, JAMA.

[86]  S. Yusuf Two decades of progress in preventing vascular disease , 2002, The Lancet.

[87]  B. MacLeod,et al.  Demographic surveillance and health equity in sub-Saharan Africa. , 2001, Health policy and planning.

[88]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[89]  I D Graham,et al.  The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[90]  M. Cabana,et al.  Why don't physicians follow clinical practice guidelines? A framework for improvement. , 1999, JAMA.

[91]  L. Wexler,et al.  Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. , 1995 .

[92]  C. Bunker,et al.  Adequacy of a single visit for classification of hypertensive status in a Nigerian civil servant population. , 1994, International journal of epidemiology.

[93]  E. Vartiainen,et al.  Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland , 1994, BMJ.

[94]  B. Glaser The Constant Comparative Method of Qualitative Analysis , 1965 .

[95]  P. Hill,et al.  Universal Health Coverage and the Right to Health: From Legal Principle to Post-2015 Indicators , 2015 .

[96]  S. Yusuf,et al.  Controversies in cardiovascular medicine Why are we failing to implement effective therapies in cardiovascular disease ? , 2013 .

[97]  Mark D. Huffman,et al.  Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2012, The Cochrane database of systematic reviews.

[98]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[99]  L. Shaw,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[100]  W. J. Elliott,et al.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2010 .

[101]  Organización Mundial de la Salud WHO report on the global tobacco epidemic, 2009: implementing smoke-free environments , 2009 .

[102]  Y. Swica,et al.  Proposal for the inclusion of misoprostol in the WHO model list of essential medicines , 2009 .

[103]  TAkING STOCk,et al.  Task shifting to tackle health worker shortages , 2007 .

[104]  S. Flottorp,et al.  Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. , 2005, The Cochrane database of systematic reviews.

[105]  J. Crofton,et al.  Tobacco and the developing world. , 1996, British medical bulletin.